-
News | 2021.05.06
Creation of the startup SPIKIMM to develop monoclonal antibodies as an innovative treatment for Covid-19
The Institut Pasteur has recently signed an exclusive worldwide license agreement with the new biotech start-up SpikImm SAS, created by Truffle Capital, for the development of anti-SARS-CoV-2 (Covid-19) monoclonal antibodies for therapeutic and diagnostic use.Monoclonal antibody therapy is one of the most innovative ways currently available to treat Covid-19 patients and prevent severe forms of...
-
News | 2020.06.04
Study reveals conditions for the onset of severe forms of COVID-19
Using state-of-the-art sequencing and bioinformatics techniques, scientists from the Institut Pasteur, working with fellow scientists from Israel and China, determined that patients with severe forms of COVID-19 presented an abnormal, ineffective lymphocyte response and a massive infiltration of inflammatory cells in the lungs.Patients with COVID-19 (see the COVID-19 fact sheet)present a...
-
Document de presse | 2021.11.18
Covid-19: Systematic review of the clinical and immunological efficacy of vaccines in immunocompromised people
The team from the Cochin-Pasteur Clinical Investigation Center of Vaccinology at Cochin AP-HP Hospital, Inserm and the University of Paris, coordinated by Prof. Odile Launay, carried out a systematic review of the literature on immunogenicity and efficacy of Covid-19 vaccines in immunocompromised individuals. It concluded that there is a risk of low immunogenicity of Covid-19 vaccines among...
-
News | 2021.10.18
The replay of the conference "COVID-19, Advances and Remaining Challenges" is available
For three days, worldwide specialists shared their views about the pandemic during a congress hosted by the Institut Pasteur. Their contributions are to be found online.
-
Article | 2020.06.16
Covid-19 risk evaluation among the household contacts of the first cases in Africa
Aim: Once the first Covid-19 cases will be identified, the spread of the SARS-CoV-2 will be related with the level of the transmission risk. This study aims to obtain an early understanding of key epidemiological characteristics in the family contacts in different African countries of the IPIN to inform decision makers about the potential spread and impact of SARS-CoV-2 infection in the closest...
-
Document de presse | 2021.07.01
Modelling study of benefits and risks associated with the COVID-19 vaccine Vaxzevria
On April 7, 2021, the European Medical Agency (EMA) concluded that thrombosis in combination with thrombocytopenia has been identified as a likely adverse event following vaccination with the COVID-19 vaccine Vaxzevria. Researchers from the Mathematical Modelling of Infectious Diseases Unit at the Institut Pasteur used a mathematical model to assess its benefits and risks in...
-
Document de presse | 2020.12.28
COVID-19: optimizing surveillance in long-term care facilities
Throughout the world, long-term care facilities have been high-risk sites for virus spread since the emergence of the COVID-19 epidemic. In this context, the capacity for timely surveillance and control of case numbers is essential in such facilities. Scientists at the Institut Pasteur have joined forces with the University of Versailles-Saint-Quentin-en-Yvelines, Inserm, and the National...
-
Document de presse | 2020.03.12
Covid-19: 20 research projects selected to fight the epidemic
At a time when the Sars-CoV-2 epidemic is continuing to spread, France is mobilizing to accelerate research into the virus and Covid-19 disease through REACTing – a consortium coordinated by Inserm. With the support of the Ministry of Solidarity and Health and the Ministry of Higher Education, Research and Innovation, the Scientific Advisory Board of REACTing has selected 20 scientific...
-
News | 2021.10.15
The Institut Pasteur de Guinée: a young institute in the midst of the COVID-19 crisis
The decision to set up an Institut Pasteur in Guinea was made in 2014 in response to the Ebola crisis. It reflects the joint determination of France and Guinea to tackle emerging outbreaks on a long-term basis for the welfare of the population. When the COVID-19 pandemic struck, how was this young institute able to fulfill its remit as a front-line laboratory?When the first case of COVID-19 was...
-
News | 2020.10.12
A feedback on 10 months of mobilization of the Institut Pasteur against covid-19
On Thursday, October 8, 2020, the Institut Pasteur in Paris organized an exceptional digital conference to review 10 months of mobilization against Covid-19, a force still in action for global health. Four experts from the Institut Pasteur were present to talk about the epidemic, tests, treatments, vaccines, scientific modelling, and answer questions from Internet users. This conference is...
